Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H
Department of Internal Medicine, Kin-ikyo Sapporo Hospital, Japan.
Acta Endocrinol (Copenh). 1988 Sep;119(1):139-44. doi: 10.1530/acta.0.1190139.
A prospective randomized trial with the conventional divided doses (10 mg 3 times daily, N = 29) and a small single daily dose (15 mg once daily, N = 25) of methimazole for the treatment of Graves' hyperthyroidism was performed. Within 8 weeks, almost 80% of the patients in both groups became euthyroid. The mean time required to achieve the euthyroid state was 6.0 +/- 2.8 and 6.0 +/- 3.8 weeks, respectively. TSH binding inhibitor immunoglobulin was found in about 90% of the patients in both groups before methimazole treatment. However, a gradual fall of its levels was observed in nearly all patients after treatment. There was no difference in the mean levels of TSH binding inhibitor immunoglobulin between the two groups during therapy. We conclude that the single daily dose regimen of 15 mg of methimazole will control Graves' hyperthyroidism in most patients, and TSH binding inhibitor immunoglobulin levels decrease in this regimen in the same way as with the conventional divided dose regimen (10 mg 3 times daily).
进行了一项前瞻性随机试验，比较传统分次给药（每日3次，每次10 mg，N = 29）和小剂量每日单次给药（每日1次，15 mg，N = 25）的甲巯咪唑治疗格雷夫斯甲亢的效果。在8周内，两组中近80%的患者甲状腺功能恢复正常。达到甲状腺功能正常状态所需的平均时间分别为6.0±2.8周和6.0±3.8周。在甲巯咪唑治疗前，两组中约90%的患者检测到促甲状腺素结合抑制性免疫球蛋白。然而，治疗后几乎所有患者的该水平均逐渐下降。治疗期间两组促甲状腺素结合抑制性免疫球蛋白的平均水平无差异。我们得出结论，每日15 mg甲巯咪唑单次给药方案可使大多数患者的格雷夫斯甲亢得到控制，且该方案中促甲状腺素结合抑制性免疫球蛋白水平下降的方式与传统分次给药方案（每日3次，每次10 mg）相同。
